News
APM
--
0.00%
--
MARA, RIOT, FCEL among premarket losers
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group MARA -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain RIOT -11% as Bitcoin crumbles despite good news rolls in.Foresight...
Seekingalpha · 1d ago
APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News
Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug.
InvestorPlace.com · 2d ago
DJ Aptorum Shares Rise 29% After Trial Approval in Canada
Dow Jones · 2d ago
Sector Update: Health Care
MT Newswires · 2d ago
Aptorum shares jump as Canada approves early-stage infection drug trial
Small-cap Aptorum (APM) soars 65% in premarket after Health Canada signs off its trial application to commence a Phase 1 study of the company's lead candidate, ALS-4, an orally administered small molecule drug
Seekingalpha · 2d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 2d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Benzinga · 2d ago
Aptorum Group Receives Health Canada Clearance To Initiate Phase 1 Clinical Trial For ALS-4, A Small Molecule Drug For Infections Caused By Staphylococcus Aureus including MRSA
Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM)))) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases,
Benzinga · 2d ago
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsid...
Business Wire · 2d ago
Aptorum Gains Canada Nod to Start Early-Stage Clinical Trial for ALS-4 to Treat Infections Caused by Staphylococcus Aureus
MT Newswires · 2d ago
Could The Aptorum Group Limited (NASDAQ:APM) Ownership Structure Tell Us Something Useful?
Simply Wall St. · 6d ago
VOXX, IRIX, RDHL and LINC among after-hours movers
Gainers: [[VOXX]] +42.9%. [[IRIX]] +22.0%. [[PXLW]] +11.8%. [[QTRX]] +7.9%. [[GNMK]] +6.9%.Losers: [[RDHL]] -9.4%. [[LINC]] -6.1%. [[LMND]] -5.3%. [[APM]] -3.9%. [[REVG]] -3.6%.
Seekingalpha · 01/11 22:55
Aptorum plans early-stage study in Canada on lead Acticule candidate
Aptorum Group (APM) has submitted a Clinical Trial Application with the regulatory authority of Canada, to commence a Phase 1 study evaluating ALS-4 for the treatment of infections caused by
Seekingalpha · 12/21/2020 13:18
Aptorum files for early-stage trial for ALS-4 in Canada
Aptorum Group (APM) has submitted a Clinical Trial Application with the regulatory authority of Canada, to commence a Phase 1 study evaluating ALS-4 for the treatment of infections caused by
Seekingalpha · 12/21/2020 13:18
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM)) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical
Benzinga · 12/21/2020 11:05
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Business Wire · 12/21/2020 11:00
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News:
BusinessWire · 12/21/2020 08:00
Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the "Company", "Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the results of its 2020 annual...
Business Wire · 12/10/2020 13:00
Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
Regulatory News:
BusinessWire · 12/10/2020 10:00
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020
Business Wire · 10/16/2020 13:00
Webull provides a variety of real-time APM stock news. You can receive the latest news about APTORUM GROUP through multiple platforms. This information may help you make smarter investment decisions.
About APM
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
More